Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors

Multiple myeloma remains an incurable plasma cell malignancy despite the rapidly evolving treatment landscape. Chimeric antigen receptor T cells targeted against BCMA have recently shown great promise in relapsed refractory multiple myeloma; however, all patients ultimately still progress from their...

Descripción completa

Detalles Bibliográficos
Autores principales: Metelo, Ana M., Jozwik, Agnieszka, Luong, Le Anh, Dominey-Foy, Delaney, Graham, Charlotte, Attwood, Charlotte, Inam, Shafqat, Dunlop, Alan, Sanchez, Katy, Cuthill, Kirsty, Rice, Carmel, Streetly, Matthew, Bentley, Trevor, Boldajipour, Bijan, Sommer, Cesar, Sasu, Barbra, Benjamin, Reuben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980918/
https://www.ncbi.nlm.nih.gov/pubmed/36874402
http://dx.doi.org/10.1158/2767-9764.CRC-21-0157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980918/
https://www.ncbi.nlm.nih.gov/pubmed/36874402
http://dx.doi.org/10.1158/2767-9764.CRC-21-0157

Ejemplares similares